Physician profile
Jordan C Walker
NPI 1770119729
$6,781.60
in general payments reported to CMS, 2019-2025
32 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.50 · 2022: $503 · 2023: $989 · 2024: $2,445 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,242.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,731.16 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,023.19 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $684.33 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $550.09 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Heartflow, INC. | $426.54 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.52 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $290.59 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $179.38 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.31 | 2023-2025 | |
| Lilly USA, LLC | $148.68 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Abiomed | $147.92 | 2024-2025 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $119.77 | 2022 | |
| Esperion Therapeutics, INC. | $117.58 | 2023-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.95 | 2023 | Lifevest |
| Shield Therapeutics INC | $86.68 | 2023-2024 | Accrufer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $84.95 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $80.30 | 2024-2025 | Capvaxive, Gardasil 9, Dificid |
| Bausch Health US, LLC | $62.92 | 2023-2024 | Aplenzin |
| Exact Sciences Corporation | $60.41 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $57.13 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $54.77 | 2025 | Nuzyra |
| Lucid Diagnostics INC. | $40.41 | 2024 | |
| Amarin Pharma, INC. | $40.01 | 2024 | |
| Seqirus USA INC | $32.37 | 2025 | Fluad, Flucelvax |
| Sumitomo Pharma America, INC. | $29.92 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $27.22 | 2024 | Trelegy Ellipta |
| Organon LLC | $23.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.13 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $19.50 | 2025 | Iqirvo |
| Medtronic, INC. | $17.80 | 2025 | Inceptiv |
| Aimmune Therapeutics, INC. | $16.83 | 2025 | Zenpep |
| Idorsia Pharmaceuticals US INC | $15.29 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.